This opportunity funds integrated phase 1 to phase 2a clinical trials for novel pharmacological interventions targeting Alzheimer's disease and related dementias. It supports agents engaging non-amyloid/non-tau mechanisms to address cognitive and neuropsychiatric symptoms across disease stages. Applications must include safety and tolerability milestones gating progression and use the UG3/UH3 phased award mechanism, streamlining early clinical evaluation.
Eligible applicants include a wide range of U.S.-based entities such as independent school districts, city and county governments, nonprofits, small businesses, tribal governments and organizations, institutions of higher education, and for-profit organizations other than small businesses. Specific
